Tarsus Pharmaceuticals Inc (NAS:TARS)
$ 50.84 1.18 (2.38%) Market Cap: 1.94 Bil Enterprise Value: 1.70 Bil PE Ratio: 0 PB Ratio: 8.18 GF Score: 49/100

Q3 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript

Nov 13, 2024 / 09:30PM GMT
Release Date Price: $46.51 (-2.24%)
Operator

Good afternoon and welcome to tsa's third quarter, 2024 financial results conference call as a reminder, this call is being recorded at this time. I would like to turn the call over to David Nakasone, head of investor relations to lead off the call. David. You may begin.

David Nakasone
Tarsus Pharmaceuticals Inc - Head, Investor Relations

Thank you. Before we begin, I encourage everyone to go to the investors section of the tarsus' website to view the earnings release and related materials we will be discussing today.

Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman Aziz Modula, our Chief Commercial Officer, Seic Niren, our Chief Operating Officer, Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer and joining us for the first time. Dr Elizabeth Yu, our newly appointed Chief Medical Officer for the Q&A portion.

I'd like to draw your attention to slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot